kimrong
$XAIR 🚨 THIS IS STARTING TO LOOK SERIOUS 🚨
Q3 revenue just hit a RECORD $2.3M — up 30% QoQ and 27% YoY.
And here’s the BIG part:
🔥 2026 revenue guidance: $8M
🔥 2027 guidance: $16–18M
🔥 2nd-gen LungFit PH is STILL under FDA review
🔥 FDA approval could significantly expand the addressable market
🔥 LungFit adoption is already accelerating
The company literally says it expects demand to increase significantly after FDA approval.
This means the market may be looking at a company BEFORE the real inflection point.
Record revenue + accelerating adoption + FDA catalyst + 2X+ projected revenue growth.
If FDA approval hits and volume starts pouring in…
XAIR could move MUCH faster than people expect. 🚀🔥
Not financial advice. High-risk small cap.
3
